Come up with a name for your new list and we'll add to it:
Meissa Vaccines raised a round of funding on May 10, 2017. Investors include
National Institutes of Health.
Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical nee…